Divi’s Labs

Divi's Labs stock tanks 12% on big miss in Q3; near-term trend 'bearish'

Analysts' average price target of Rs 3,862, however, indicates significant upside. The near-term trend remains bearish

Brokerages downgrade Divi's Labs post Q2 letdown; stock falls 11% in 2 days

EBITDA margins declined 767 bps YoY to 33.5 per cent due to high energy and transport costs.

Growth worries to keep Divi's Labs under pressure in the near term

Valuations, too, are on the higher side, say brokerages

Six Indian drug firms that are doing serious business in coronavirus times

The world's race for a coronavirus drug hinges on Indian companies working with their global peers. Business Standard tracks six companies to feel the pulse of Indian pharma

Divi's Labs: New capex, margin expansion to support earnings growth

Brokerages expect the company's net profits to grow by 30 per cent annually over FY20-23

Infosys, PI Industries, ICICI Bank: Top picks of brokerages for Samvat 2077

According to Axis Securities, the small and midcaps are picking up steam and they should deliver solid returns in 2021 as economic uncertainties will reduce and volatility will decline

Divi's Laboratories begins commercial production at Visakhapatnam unit

Divi's Laboratories, established in Hyderabad, is a pharmaceutical company with two manufacturing units

Choke in API supplies from China creates huge opportunity for Divi's Labs

Niche capabilities and absence of regulatory overhangs are other key positives

Expansions, clean track record helping Divi's Labs tap new opportunities

The current margin pressure will also get mitigated by tax benefits and operational efficiencies

Divi's Labs gains 5% as USFDA issues no observations for Telangana plant

The Company's Unit-I facility at Lingojigudem, Bhuvanagiri Yadadri district, Telangana has been inspected by the USFDA from the November 11, to November 15, 2019.

Divi's Labs Q2 net down 12% at Rs 357 cr; revenue rises to Rs 1446 cr

The company had posted a net profit of Rs 403.72 crore in the July-September period of 2018-19.

Divi's Labs cash in on bullish sentiment, strong growth prospects

The second largest pharma player by market value is also expanding capacities to push earnings

At Rs 58.8 cr, Murali of Divi's Lab highest paid pharma honcho in FY19

According to Divis latest annual report, Murali Divi, the promoter-executive,was given a hike of 46.3 per cent in his remuneration over the previous fiscal

Higher raw material costs, adverse product mix weigh on Divi's Labs

Higher raw material costs fuelled by the rising Chinese chemical prices were the major reason for margins disappointment

Divi's Labs surges 14% on strong Q2 results; stock hits record high

The stock surged 14% to Rs 1,433 on the BSE in early morning trade on Monday, after reported a healthy 92% Y-o-Y jumped in net profit at Rs 3.98 billion in September quarter.

US FDA lifts import alert on Divi's Lab Vizag unit in record seven months

This is seen as unprecedented for Indian drug makers

Divi's Lab shares surge 7% as Q1 net rises

At NSE, shares of the company jumped 6.44% to touch its one-year high of Rs 1,271

Divi's Labs Q1 net up 23% at Rs 301 crore

Total income from operations at Rs 1,008 crore, up 25%; expenditure during this period grew by 18.4%